HX8

Drug Profile

HX8

Alternative Names: Anti-HSV antibody-HX8

Latest Information Update: 18 May 2007

Price : $50

At a glance

  • Originator ReProtect LLC
  • Developer Biolex; Dow Chemical; ReProtect LLC
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Herpes simplex virus infections

Most Recent Events

  • 18 May 2007 Discontinued - Preclinical for Herpes simplex virus infections in USA (Vaginal)
  • 06 May 2004 Epicyte Pharmaceutical has been acquired and merged into Biolex
  • 11 Sep 2002 A Plantibodies™ candidate anti-HSV antibody (HX8) has been identified
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top